Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track HOWL with free AI briefings, catalyst countdowns, and dilution alerts.

HOWL · Werewolf Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$41.9M Cash on Hand
107.5mo Cash Runway
Follow HOWL by email Get an email when HOWL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about HOWL, unsubscribe in one click. Privacy

📣 What HOWL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Engineered IL-12 Prodrug WTX-330 Advanced or Metastatic Solid Tumors Phase 1/2 · NCT06939283 Completed
Lecomkafusp Alfa (WTX-124) Metastatic Solid Tumor Phase 1 · NCT05479812 Completed

Also used in these trials (approved or third-party drugs, not HOWL's own candidates): Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

HOWL holds $41.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.2M/quarter from operations, an estimated runway of 107.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 40 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HOWL files for a raise →

👥 Who Owns HOWL

Insiders 10.5% Other 5%+ holders 5.2% Institutions (63 holders) 42.3% Public and other holders 42%
HolderTypeShares% of sharesAs of
MPM BioVentures 2014, L.P.
Former 10% Owner
Insider 4,784,111 9.84% 2025-12-02
Ansbert Gadicke
Former 10% Owner
Includes shares also reported by MPM BioVentures 2014, L.P., counted once
Insider 4,784,111 9.84% 2025-12-02
BALYASNY ASSET MANAGEMENT L.P. Institution (13G, 5%+) 3,040,251 6.26% 2026-09-30
MOLL PETER 5%+ holder (13G) 2,537,138 5.22% 2026-09-18
RA CAPITAL MANAGEMENT, L.P.
10% owner
Insider 303,719 0.62% 2026-06-17
Michael J. Urban
VP of Finance & Corp. Contr.
Insider 5,284 0.01% 2026-02-13

Share count 48,599,066 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full HOWL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HOWL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.